Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Gains from Investment Securities: 2021-2024

Historic Gains from Investment Securities for Biofrontera (BFRI) over the last 4 years, with Dec 2024 value amounting to $1.4 million.

  • Biofrontera's Gains from Investment Securities rose 192.69% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 134.41%. This contributed to the annual value of $1.4 million for FY2024, which is 1265.74% up from last year.
  • Per Biofrontera's latest filing, its Gains from Investment Securities stood at $1.4 million for FY2024, which was up 1,265.74% from $99,486 recorded in FY2023.
  • Biofrontera's Gains from Investment Securities' 5-year high stood at $1.4 million during FY2024, with a 5-year trough of $86,951 in FY2022.
  • For the 3-year period, Biofrontera's Gains from Investment Securities averaged around $515,052, with its median value being $99,486 (2023).
  • As far as peak fluctuations go, Biofrontera's Gains from Investment Securities slumped by 85.92% in 2022, and later surged by 1,265.74% in 2024.
  • Over the past 4 years, Biofrontera's Gains from Investment Securities (Yearly) stood at $617,696 in 2021, then crashed by 85.92% to $86,951 in 2022, then climbed by 14.42% to $99,486 in 2023, then soared by 1,265.74% to $1.4 million in 2024.